Suppr超能文献

与李-佛美尼综合征相关的泌尿生殖道恶性肿瘤:单机构经验回顾

Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience.

作者信息

Murray Katie S, Spaliviero Massimiliano, Tonorezos Emily S, Lacouture Mario E, Tap William D, Oeffinger Kevin C, Vargas Hebert Alberto, Eastham James A

机构信息

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Surgery, Division of Urology, University of Missouri, Columbia, MO.

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Stony Brook Medicine, SUNY at Stony Brook, Stony Brook, NY.

出版信息

Urology. 2018 Sep;119:55-61. doi: 10.1016/j.urology.2018.06.008. Epub 2018 Jun 21.

Abstract

OBJECTIVE

To report a case of pelvic angiosarcoma in a 27-year-old man with Li-Fraumeni Syndrome (LFS) and evaluate the presentation and timeline of genitourinary (GU) tract involvement in LFS patients.

METHODS

We retrospectively identified 39 LFS patients treated at our institution between 2000 and 2014; 7 (18%) had experienced a GU malignancy or an LFS-related malignancy involving the GU tract. Clinical characteristics, including dates of onset of first GU tract malignancies; pathologic findings; multimodal management; and familial history of LFS were reviewed.

RESULTS

Median age at first malignancy was 14.0 years (interquartile range [IQR] 5.5-24.0). There was a slight male predominance (4 of 7). Median time between first malignancy and the malignancy involving the GU tract was 10.1 years (IQR 8.0-19.5). Six of the 7 patients (86%) had a form of sarcoma involving the GU tract; 1 developed adrenocortical carcinoma. The cancer pedigree of all patients showed LFS-associated malignancies in family members. Multimodal management included surgical resection in 6 patients with adjuvant chemotherapy or radiotherapy in 1 patient each. One patient received chemotherapy only. Following diagnosis of malignancy involving the GU tract, 5 of the 7 patients developed additional primary malignancies. At a median follow-up of 4.7 years (IQR 3.0-12.1), 2 patients are alive, 3 died of disease, and 1 died of unknown cause. One patient was lost at follow-up.

CONCLUSION

Continued follow-up of LFS cancer patients aimed at the determination of optimal screening, management, and surveillance protocols is recommended and may result in longer survival expectations.

摘要

目的

报告一例27岁患有李-弗劳梅尼综合征(LFS)的男性盆腔血管肉瘤病例,并评估LFS患者泌尿生殖道受累的表现及时间进程。

方法

我们回顾性分析了2000年至2014年在我院接受治疗的39例LFS患者;其中7例(18%)发生了泌尿生殖系统恶性肿瘤或涉及泌尿生殖道的LFS相关恶性肿瘤。回顾了临床特征,包括首次泌尿生殖道恶性肿瘤的发病日期;病理结果;多模式治疗;以及LFS家族史。

结果

首次发生恶性肿瘤的中位年龄为14.0岁(四分位间距[IQR]5.5 - 24.0)。男性略占优势(7例中的4例)。首次恶性肿瘤与涉及泌尿生殖道的恶性肿瘤之间的中位时间为10.1年(IQR 8.0 - 19.5)。7例患者中有6例(86%)发生了涉及泌尿生殖道的肉瘤;1例发生肾上腺皮质癌。所有患者的癌症谱系均显示家庭成员中有LFS相关恶性肿瘤。多模式治疗包括6例患者接受手术切除,1例患者接受辅助化疗,1例患者接受放疗。1例患者仅接受化疗。在诊断出涉及泌尿生殖道的恶性肿瘤后,7例患者中有5例发生了额外的原发性恶性肿瘤。中位随访4.7年(IQR 3.0 - 12.1),2例患者存活,3例死于疾病,1例死因不明。1例患者失访。

结论

建议对LFS癌症患者进行持续随访,以确定最佳筛查、治疗和监测方案,这可能会带来更长的生存预期。

相似文献

1
Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience.
Urology. 2018 Sep;119:55-61. doi: 10.1016/j.urology.2018.06.008. Epub 2018 Jun 21.
2
Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.
Breast Cancer Res Treat. 2020 May;181(1):181-188. doi: 10.1007/s10549-020-05612-7. Epub 2020 Apr 3.
3
Li-Fraumeni syndrome presenting as mucosal melanoma: Case report and treatment considerations.
Head Neck. 2017 Feb;39(2):E20-E22. doi: 10.1002/hed.24594. Epub 2016 Oct 11.
4
Breast cancer in patients with Li-Fraumeni syndrome - a case-series study and review of literature.
Breast Cancer (Dove Med Press). 2017 Mar 23;9:207-215. doi: 10.2147/BCTT.S134241. eCollection 2017.
5
Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
J Steroid Biochem Mol Biol. 2019 Jun;190:250-255. doi: 10.1016/j.jsbmb.2019.04.011. Epub 2019 Apr 8.
6
Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma.
Pediatr Blood Cancer. 2007 Mar;48(3):345-8. doi: 10.1002/pbc.20795.
7
Li-Fraumeni syndrome: a case report.
Vojnosanit Pregl. 2014 Dec;71(12):1159-62. doi: 10.2298/vsp1412159i.
8
[Li Fraumeni syndrome: a case with multiple primary cancers and presenting a germline p53 mutation].
Ann Biol Clin (Paris). 2010 May-Jun;68(3):346-50. doi: 10.1684/abc.2010.0441.
9
Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician.
Rev Assoc Med Bras (1992). 2015 May-Jun;61(3):282-9. doi: 10.1590/1806-9282.61.03.282.
10
The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report.
Yale J Biol Med. 2015 Jun 1;88(2):181-5. eCollection 2015 Jun.

引用本文的文献

1
Germline predisposition to genitourinary rhabdomyosarcoma.
Transl Androl Urol. 2020 Oct;9(5):2430-2440. doi: 10.21037/tau-20-76.

本文引用的文献

1
Li-Fraumeni Syndrome and p53 in 2015: Celebrating their Silver Anniversary.
Clin Invest Med. 2016 Feb 1;39(1):E37-47. doi: 10.25011/cim.v39i1.26328.
2
Prostate Cancer and Li-Fraumeni Syndrome: Implications for Screening and Therapy.
Urol Case Rep. 2015 Feb 7;3(2):21-3. doi: 10.1016/j.eucr.2015.01.002. eCollection 2015 Mar.
3
Germline Mutations in Predisposition Genes in Pediatric Cancer.
N Engl J Med. 2015 Dec 10;373(24):2336-2346. doi: 10.1056/NEJMoa1508054. Epub 2015 Nov 18.
4
Cancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencing.
Eur J Pediatr. 2015 Aug;174(8):987-97. doi: 10.1007/s00431-015-2565-x. Epub 2015 May 16.
5
Germline TP53 variants and susceptibility to osteosarcoma.
J Natl Cancer Inst. 2015 Apr 20;107(7). doi: 10.1093/jnci/djv101. Print 2015 Jul.
6
Mutant p53 in cancer: new functions and therapeutic opportunities.
Cancer Cell. 2014 Mar 17;25(3):304-17. doi: 10.1016/j.ccr.2014.01.021.
7
Li-Fraumeni syndrome: cancer risk assessment and clinical management.
Nat Rev Clin Oncol. 2014 May;11(5):260-71. doi: 10.1038/nrclinonc.2014.41. Epub 2014 Mar 18.
9
Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.
Oncogene. 2014 Mar 20;33(12):1601-8. doi: 10.1038/onc.2013.106. Epub 2013 Apr 15.
10
P53 and its molecular basis to chemoresistance in breast cancer.
Expert Opin Ther Targets. 2012 Mar;16 Suppl 1:S23-30. doi: 10.1517/14728222.2011.640322. Epub 2012 Feb 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验